Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial tested an investigational medicine called PF-06817024 across three separate parts. In total, 97 people took part. Part 1 tested different doses of the medicine given either directly into a vein (intravenously) or by injection under the skin (subcutaneously) in healthy volunteers, with some participants receiving a placebo (a dummy treatment with no active ingredient) for comparison. Part 2 involved people with a condition called chronic rhinosinusitis with nasal polyps (ongoing sinus inflammation with growths in the nose), and Part 3 involved people with atopic dermatitis (a type of eczema). The trial's primary focus — meaning the main things it set out to measure — was tracking undesirable medical events (called adverse events) that occurred during the study, to see how many participants experienced them and how serious they were. The reported data shows that in Part 1, the number of participants who experienced any adverse event during the study ranged across the different dose groups. For example, all 6 participants in the 10 mg intravenous group and all 6 in the 300 mg intravenous group reported at least one such event, while 1 out of 4 participants in the 100 mg multiple-dose group reported one. Among those whose adverse events were judged by the study doctor to be possibly related to the study medicine, numbers were generally low — for instance, 2 out of 6 in the 10 mg group, 3 out of 6 in the 300 mg group, and 1 out of 6 in the 1,000 mg group. Only 1 participant across all of Part 1 stopped the study permanently because of an adverse event. In Part 2 (the nasal polyp group), the reported data shows that 10 out of 11 participants receiving the medicine and 8 out of 9 receiving placebo experienced at least one adverse event, with 5 and 3 of those respectively judged as possibly related to treatment. No serious adverse events — meaning events that were life-threatening, required hospitalisation, or caused lasting harm — were reported in the medicine groups across Parts 1 or 2, though 1 serious adverse event was reported in the Part 2 placebo group. Data for Part 3 (the eczema group) was not reported for these primary outcome measures in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39215351) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 1 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- (Part 1) Healthy men, or women who cannot become pregnant, between 18 and 55 years old
- (Part 2) Men, women who cannot become pregnant, or women who have had their tubes tied or removed, between 18 and 65 years old, who also have at least 2 of these symptoms: blocked/stuffy nose, runny nose, pain or pressure in the face, or reduced/lost sense of smell
- (Part 3) Men or women between 18 and 75 years old who have moderate-to-severe Atopic Dermatitis (a skin condition causing irritated, itchy skin), and who agree to avoid prolonged sun exposure, tanning booths, sun lamps, or other UV light sources during the study
Who may not be able to join:
- (Parts 1, 2, and 3) People with significant health conditions such as heart, psychiatric, autoimmune, or kidney problems, or who test positive for drugs in a urine test, have had a fever in the last 7 days, or have had an active infection in the last 28 days
- (Part 2) People who have had an allergic reaction to topical lidocaine (a numbing gel/cream), or who have had nasal surgery within the last 6 months
- (Part 3) People who have recently received a live or weakened vaccine, have skin conditions other than Atopic Dermatitis, or are currently using certain medications called JAK inhibitors or biologics (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With All-causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part 1; Number of Participants With Treatment-Related TEAEs and SAEs in Part 1; Number of All-Causality TEAEs According to Severity in Part 1; Number of Participants With Permanent Discontinuation Due to TEAEs in Part 1; Number of Participants With All-Causality TEAEs and SAEs in Part 2; Number of Participants With Treatment-Related TEAEs and SAEs in Part 2; Number of All-Causality TEAEs According to Severity in Part 2; Number of Participants With Permanent Discontinuation D...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.